To implement the newly-revised Provisions for Drug Registration, the State Food and Drug Administration (SFDA) organized the drafting of Implementation Measures for Special Approval Procedures for Drug Registration (interim) and now soliciting public opinions.
In the draft four kinds of drugs can get priority review called "Green Channel":
First class: Active ingredient and its active ingredients extracted from plant, animal and mineral never marketed in China; new found medicinal herb and its preparations
Second class: New chemical entity and its preparations never marketed in any country, biological product never marketed in any country.
Third class: New drug for AIDS, malignant tumors and rares disease and with obviously clinical advantages.
Forth class: New drug for the diseases for which no effective therapy.